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Office of the Attorney General
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Ms. Knight,

I hereby request the preparation of a title and summary for the enclosed proposed
initiative measure.

- GerZiRWkdagZn
Proponent

Enclosed:

Proponent's Voter Registration Address
Text of Proposed Initiative Measure
Payment for title and summary preparation

SECTION 1. Title.
This Act shall be known as the "Affordable and Safe Prescription Drugs for All Californians
Act"
SECTION 2. Findings and Declarations.
The People of California find and declare the following:
Prescription drugs cost 70% more in California than they do in other countries. Drug companies
knowingly sell dangerous drugs.
Other countries use their buying power to negotiate prescription drug discounts. The State of
California negotiates drug discounts on behalf of state workers, elected officials and the
Governor. Existing laws do not allow most Californians to access similar discounts.
Therefore, the People of California declare that reform is necessary. First, all Californians shall
be allowed to join a discount program to access affordable prescription drugs at local

pharmacies. This purchasing program will operate on a key market principle: the bigger the
buyer, the better the price. Second, unfair price gouging by drug companies will be controlled.
Third, drug companies and marketers will be required to tell doctors and the public about the
health risks of prescription drugs. Drug companies and marketers shall pay a fee to cover the
costs of administering these new laws so that this reform will cost taxpayers nothing.
SECTION 3. Purpose and Intent.
The purpose of this Act is to provide all Californians access to affordable and safe prescription
drugs.
SECTION 4. Part 9 (commencing with Section 22980) is added to Division 5 of Title 2 of the
Government Code, to read:
22980. This chapter shall be known and be cited as the Affordable and Safe Prescription Drugs
for All Californians Act ("Act")
Article I. Voluntary Access to Prescription Drug Discounts
22981. Any individual, regardless of income or insurance status, shall be allowed to join a
prescription drug discount program administered by the Board of Administration of the Public
Employees' Retirement System ("Board").
22982. The Board shall issue a pharmacy card to each new enrollee to access prescription drug
discounts at the same pharmacies and pharmacy networks available to state workers. The Board
shall provide enrollees access to a mail-order pharmacy option.

22983. The Board shall establish procedures for continuous open enrollment to the discount
program. Enrollment forms shall be made available on the Board's Web site, at participating
pharmacies, physician offices and at various other locations deemed appropriate by the Board.
22984. The Board may require an enrollee to pay an annual fee that proportionally reflects the
administrative cost of providing prescription drug discounts to the enrollee, except that no
enrollee fee shall be required if licensing fees and fines collected under Article 25 of Chapter 9
of Division 2 of the Business and Professions Code provide for the full cost of the program. The
annual enrdlee fee shall not exceed ten dollars ($10) per year adjusted annually to reflect the rate
of inflation.
22985. The Board may enter into contracts with entities offering services related to the
administration of pharmacy benefits, or with an entity that negotiates price discounts, rebates or
other savings on prescription drugs with prescription drug manufacturers, wholesalers, or
pharmacies.
22986. (a) The Board shall inform the public about their eligibility under the Act through press
releases, public services announcements, television, radio and newspaper advertisements,
announcements on state websites and written materials, and other means. The Board shall
coordinate outreach activities with the California Department of Aging and other state and local
agencies.
(b) No outreach material shall contain the name or likeness of a prescription drug,

pharmaceutical drug manufacturer, or elected official. The annual cost of these outreach
activities shall not exceed $1 million. If deemed appropriate by the Board, additional outreach
and advertising expenses may be approved by the legislature by a statute passed in each house by
roll call vote entered in the journal, fifty percent plus one of the membership concurring. Annual
outreach costs shall be paid out of the Prescription Drug Discount Fund.
22987. The Prescription Drug Discount Fund is hereby established and shall be maintained in the
State Treasury to accept fees related to enrollment in the program and licensing fees and fines
collected under Article 25 of Chapter 9 of Division 2 of the Business and Professions Code.
Notwithstanding Section 13340 of the Government Code, the fund is hereby continuously
appropriated to the Board for purposes of the administration and maintenance of the
pharmaceutical purchasing program.
22988. The Board may request from the state Legislature, and the Legislature shall provide, up
to $5,000,000 to pay for initial startup costs associated with the implementation of this Act.
Licensing fees and fines collected under Article 25 of Chapter 9 of Division 2 of the Business
and Professions Code shall be used to repay monies provided to pay for initial startup costs.
22989. Enrollees shall pay the discounted price for prescription drugs negotiated by the Board at
participating pharmacies. The amount to be paid for those drugs by enrollees may include a
pharmacy dispensing fee of no more than three dollars and fifty cents per prescription adjusted
annually to reflect the rate of inflation.

22990. Following public comment, the Board may adopt a preferred drug list. If the Board
adopts a preferred drug list, the Board shall provide for periodic public review of, and consider
suggested changes to, the preferred drug list.
2299 1. The Board may adopt all necessary rules and regulations to carry out the provisions of
this Act. The Board shall have the authority reasonably necessary to carry out the powers and
responsibilities expressly granted or imposed upon it under this Act.
Article 2. b d Drug Company Profiteering
22995. Profiteering in prescription drugs is unlawful and is subject to the provisions of this
section. The provisions of this section apply to pharmaceutical drug manufacturers.
(a) A pharmaceutical drug manufacturer engages in illegal profiteering if that manufacturer:
(I) Exacts or demands an excessive price;
(2) Exacts or demands a price or terms that lead to any unjust or unreasonable profit;
(3) Discriminates unreasonably against any person in the sale, exchange, distribution or handling
of prescription drugs dispensed or delivered in the State; or
(4) Intentionally prevents, limits, lessens or restricts the sale or distribution of prescription drugs
in this State in retaliation for the provisions of this chapter.
(b) The Board shall adopt, no later than six (6) months after voter approval of this measure and
following public hearings, regulations determining excessive price and unjust or unreasonable
profit.

(c) Each violation of this section is a civil violation for which the Attorney General or any person
acting for the interests of itself, its members or the general public may obtain, in addition to other
remedies, disgorgement and restitution, injunctive relief and a civil penalty in an amount of
$100,000, plus the costs of suit, including necessary and reasonable investigative costs,
reasonable expert fees and reasonable attorney's fees.
SECTION 5. Safe Prescription Drugs

Article 25 (commencing with Section 4450) is added to Chapter 9 of Division 2 of the Business
and Professions Code, to read:

4450. (a) No person may act as a prescription drug marketer unless such person, and the
pharmaceutical drug manufacturer represented by the person, has first secured a license from the
Board of Pharmacy. The Board of Pharmacy shall implement this Article no later than six (6)
months after voter approval of this measure.
(b) A person or manufacturer licensed under this Article:

(I) Shall not engage in any unfair or deceptive acts or practices.

(2) Shall disclose to a physician or any other person licensed to prescribe prescription drugs in
this state, the health risks of, and results of any clinical trials regarding the health risks of, each
prescription drug directly marketed to the physician or other person authorized to prescribe
prescription drugs.
(c) A manufacturer licensed under this section shall disclose on the manufacturer's website the
health risks of, and the results of any clinical trials regarding the health risks of, each prescription
drug marketed by a licensed marketer employed by or representing the manufacturer in this state.
4451. A person or pharmaceutical drug manufacturer who violates a provision of this Article
may be subject to revocation or suspension of the license granted under this Article.
4452. (a) The Board of Pharmacy shall require each licensee that is not a pharmaceutical drug
manufacturer to pay an annual fee of $750.00.

(b) The Board of Pharmacy shall require a manufacturer employing or contracting for a
prescription drug marketer or marketers in this state to pay an annual fee of $25,000 per
manufacturer.
4453. A person other than a pharmaceutical drug manufacturer who violates a provision of
Article, including a person who engages in the activities of a prescription drug marketer after his
or her license has been revoked or suspended, shall be fined $5,000 by the Board of Pharmacy. A
manufacturer who violates a provision of this Article shall be fined $25,000 by the Board of
Pharmacy. The Attorney General or a district attorney, county council, city attorney, or city
prosecutor may bring a civil action to enforce the provisions of this Article. Each unlawful act of
prescription drug promotional or marketing activity shall constitute a separate violation of this
Article.
4454. License fees and fines shall be deposited into the Prescription Drug Discount Fund, as
defined under Section 22987 of the Government Code, to pay for costs associated with the
Affordable and Safe Prescription Drugs for All Californians Act. No more than $2,000,000 of
these fees and fines may be retained annually by the Board of Pharmacy to pay for necessary
expenses related to the licensing and oversight of marketers and manufacturers. Additional
funds to implement this section may be approved by the legislature by a statute passed in each
house by a roll call vote entered in the journal, fifty percent plus one of the membership
concurring.
4455. (a) The Board of Pharmacy may adopt all necessary rules and regulations to carry out the
provisions of this Article. The Board of Pharmacy shall have the authority reasonably necessary
to carry out the powers and responsibilities expressly granted or imposed upon it under this
Article.
(b) In the event that the Board of Pharmacy ceases to exist, or its duties are subsumed by, or
transferred to, another entity, the authorities and duties of this Article shall be transferred to the
California Department of Health Services.

4456. For the purposes of this Article:
(a) "prescription drug marketer7'or "marketer" means a person who, while employed by or under
contract to represent a pharmaceutical manufacturing company, engages in pharmaceutical
detailing, promotional activities, or other marketing of prescription drugs in this state to any
physician or any other person licensed to prescribe prescription drugs.
@) "Pharmaceutical drug manufacturer" or "manufacturer" means any entity which is engaged in
the production, preparation, propagation, compounding, conversion, or processing of prescription
drugs, either directly or indirectly by extraction from substances of natural origin, or
independently by means of chemical synthesis, or by a combination of extraction and chemical
synthesis, or any entity engaged in the packaging, repackaging, labeling, relabeling, or
distribution of prescription drugs. The term does not include a licensed pharmacist.

(c) "prescription drug" means any of the following:
(1) Any drug that bears the legend "Caution: federal law prohibits dispensing without
prescription," "Rx only," or words of similar import.
(2) Any drug or device that, pursuant to federal or state law, may be dispensed only with a
prescription, or that is furnished pursuant to Section 4006 of the Business and Professions Code.
(3) "prescription drug" does not include labeled veterinary drugs.
(d) "marketed means any promotional or marketing activity carried out by the prescription drug
marketer or pharmaceutical drug manufacturer.
(e) "Board of Pharmacy" means the California Board of Pharmacy.
(f) "clinical trial" means a systematic evidenced based research study designed to answer
specific questions about new or existing prescription drugs, or new ways of using known
treatments.
SECTION 6. Joint Purchasing
Section 22851 of the Government Code is amended to read:
The Board may enter into any joint purchasing arrangement with private or public entities if the
arrangement does not jeopardize the system's tax status or its governmental plan status.
SECTION 7. Definitions and Technical Matters
Section 22998 and 22999 are added to Part 9 of Division 5 of Title 2 of the Government Code, to
read:
22998. For the purposes of this part:
(a) "Enrollee" means any individual enrolled in the prescription drug discount program provided
by the Affordable and Safe Prescription Drugs for All Californians Act.

(b) "Program" or "discount program" means the prescription drug discount program provided by
the Affordable and Safe Prescription Drugs for All Californians Act.

(c) "Board" means the Board of Administration of the Public Employees' Retirement System.
(d) "pharmaceutical drug manufacturer" or "manufacturer" means any entity which is engaged
in the production, preparation, propagation, compounding, conversion, or processing of
prescription drugs, either directly or indirectly by extraction from substances of natural origin, or
independently by means of chemical synthesis, or by a combination of extraction and chemical
synthesis, or any entity engaged in the packaging, repackaging, labeling, relabeling or
distribution of prescription drugs. The term does not include a licensed pharmacist.
(e) "prescription drug" means any of the following:
(I) Any drug that bears the legend "Caution: federal law prohibits dispensing without
prescription," "Rx only," or words of similar import.
(2) Any drug or device that, pursuant to federal or state law, may be dispensed only with a
prescription, or that is furnished pursuant to Section 4006 of the Business and Professions Code.
(3) "prescription drug" does not include labeled veterinary drugs.
22999. (a) This Act shall be broadly construed and applied in order to fully promote its
underlying purposes. If any provision of this initiative conflicts directly or indirectly with any
other provisions of law, or any other statute previously enacted by the Legislature, it is the intent
of the voters that such provisions shall be null and void to the extent that they are inconsistent
with this initiative and are hereby repealed.
@) No provision of this Act may be amended by the legislature except to further the purposes of

that provision by a statute passed in each house by roll call vote entered in the journal, two-third
of the membership concurring, or by a statute that becomes effective only when approved by the
electorate. No amendment by the legislature shall be deemed to further the purposes of this Act
unless it furthers the purpose of the specific provision of this Act that is being amended. In any
judicial action with respect to any legislative amendment, the court shall exercise its independent
judgment as to whether or not the amendment satisfies the requirements of this subsection.
(c) If any provision of this Act or the application thereof to any person or circumstances is held
invalid, that invalidity shall not affect other provisions or applications of the Act that can be
given effect in the absence of the invalid provision or application. To this end, the provisions of
this Act are severable.
(d) In the event that this measure and another measure or measures relating to prescription drug
purchasing, discounts, or price negotiation shall appear on the same statewide election ballot, the
provisions of the other measure or measures shall be deemed in conflict with this measure. In
the event that this measure receives a greater number of affirmative votes, the provisions of this
measure shall prevail in their entirety, and the other measure or measures shall be null and void.

